Abstract
Over the last two decades, occurrence of bacterial resistance to commonly used antibiotics has necessitated the development of safer and more potent anti-microbial drugs. However, the development of novel antibiotics is severely hampered by adverse side effects, such as drug-induced liver toxicity. Several antibacterial drugs are known to have the potential to cause severe liver damage. The major challenge in developing novel anti-microbial drugs is to predict, with certain amount of probability, the drug–induced toxicity during the pre-clinical stages, thus optimizing and reducing the time and cost of drug development. Toxicogenomics approach is generally used to harness the potential of genomic tools and to understand the physiological basis of drug-induced toxicity based on the in-depth analysis of Metagenomic data sets, i.e., transcriptional, translational or metabolomic profiles. Toxicogenomics, therefore, represents a new paradigm in the drug development process, and is anticipated to play an invaluable role in future to develop safe and efficacious medicines, by predicting the toxic potential of a new chemical entity (NCE) in early stages of drug discovery. This review examines the toxicogenomic approach in predicting the safety/toxicity of novel anti-microbial drugs, and analyses the promises, pitfalls and challenges of applying this powerful technology to the drug development process.
Keywords: Toxicogenomics, Safety, Liver toxicity, Kidney toxicity, Anti-microbial, Gene expression profiling.
Infectious Disorders - Drug Targets
Title:Role of Toxicogenomics in the Development of Safe, Efficacious and Novel Anti-microbial Therapies.
Volume: 13 Issue: 3
Author(s): Jamal S.M. Sabir, Osama A. Abu-Zinadah, Roop S. Bora, Mohamed M.M. Ahmed and Kulvinder S. Saini
Affiliation:
Keywords: Toxicogenomics, Safety, Liver toxicity, Kidney toxicity, Anti-microbial, Gene expression profiling.
Abstract: Over the last two decades, occurrence of bacterial resistance to commonly used antibiotics has necessitated the development of safer and more potent anti-microbial drugs. However, the development of novel antibiotics is severely hampered by adverse side effects, such as drug-induced liver toxicity. Several antibacterial drugs are known to have the potential to cause severe liver damage. The major challenge in developing novel anti-microbial drugs is to predict, with certain amount of probability, the drug–induced toxicity during the pre-clinical stages, thus optimizing and reducing the time and cost of drug development. Toxicogenomics approach is generally used to harness the potential of genomic tools and to understand the physiological basis of drug-induced toxicity based on the in-depth analysis of Metagenomic data sets, i.e., transcriptional, translational or metabolomic profiles. Toxicogenomics, therefore, represents a new paradigm in the drug development process, and is anticipated to play an invaluable role in future to develop safe and efficacious medicines, by predicting the toxic potential of a new chemical entity (NCE) in early stages of drug discovery. This review examines the toxicogenomic approach in predicting the safety/toxicity of novel anti-microbial drugs, and analyses the promises, pitfalls and challenges of applying this powerful technology to the drug development process.
Export Options
About this article
Cite this article as:
Sabir S.M. Jamal, Abu-Zinadah A. Osama, Bora S. Roop, Ahmed M.M. Mohamed and Saini S. Kulvinder, Role of Toxicogenomics in the Development of Safe, Efficacious and Novel Anti-microbial Therapies., Infectious Disorders - Drug Targets 2013; 13 (3) . https://dx.doi.org/10.2174/1871526511313030009
DOI https://dx.doi.org/10.2174/1871526511313030009 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Induced Adaptive Resistance to Nitrooxidative Stress in the CNS: Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry The Role of Endothelial Progenitor Cells and Statins in Endothelial Function: A Review
Cardiovascular & Hematological Agents in Medicinal Chemistry An Old Drug with a New Purpose: Cardiovascular Actions of Acetaminophen (Paracetamol)
Current Drug Targets - Cardiovascular & Hematological Disorders Targeting the Mitochondrial Electron Transport Chain Complexes for the Induction of Apoptosis and Cancer Treatment
Current Pharmaceutical Biotechnology Effects of Aging and Diet on Cardioprotection and Cardiometabolic Risk Markers
Current Pharmaceutical Design Targeting Tumor Proteasome with Traditional Chinese Medicine
Current Drug Discovery Technologies The Origins of Aging: Evidence that Aging is an Adaptive Phenotype
Current Aging Science Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges
Current Drug Metabolism Defining Cell Identity by Comprehensive Gene Expression Profiling
Current Medicinal Chemistry The Roles of Mesenchymal Stem Cells in Tissue Repair and Disease Modification
Current Stem Cell Research & Therapy Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Reactive Oxygen Species in Myocardial Reperfusion Injury: From Physiopathology to Therapeutic Approaches
Current Pharmaceutical Biotechnology Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) Apoptosis: A Potential Therapeutic Target for Retinal Degenerations
Current Neurovascular Research Berberine in the Treatment of Diabetes Mellitus: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets MicroRNAs as Modulators of the Platelet Proteome
Current Proteomics c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Targeting the Inflammatory Response in Healing Myocardial Infarcts
Current Medicinal Chemistry iTRAQ-Based Quantitative Proteomics Analysis Reveals the Invasion Mechanism of <i>Spiroplasma eriocheiris</i> in 3T6 Cells
Current Proteomics Can We Move Forward After ADVANCE?
Vascular Disease Prevention (Discontinued)